Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
2023-11-19 21:37:59 ET Summary Soros Fund Management's 13F portfolio value increased by 10% to $7.05B, with 209 positions. Top three individual stocks held were Horizon Therapeutics, Activision Blizzard, and Alphabet. New stakes included Activision Blizzard, Abcam plc, Novo No...
2023-11-07 19:06:24 ET Summary A phase 2 study is being advanced using EPI-7386 in combination with enzalutamide to treat patients with metastatic castration-resistant prostate cancer; Positive updated PSA data presented at medical conference. EPI-7386 is being advanced as a monot...
2023-11-05 12:17:29 ET Summary The UST yield curve has steepened and this could provide an opportunity to buy US banking stocks on weakness in a no-recession scenario. Japan and Eurozone exporters can benefit from a global downturn due to easier central bank policies depreciating ...
2023-10-27 16:13:47 ET Summary Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently a...
2023-10-23 14:25:26 ET More on Seattle Genetics Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Seagen ticks higher as EU approves $43B sale to Pfizer Pfizer likely turned over all documents to FTC for Seagen acquistion - r...
2023-10-13 09:38:00 ET More on Astellas Pharma ADR Astellas: Earnings Power, Asset Factors Attractive, Reiterate Hold On Valuation Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript Merck succeeds in Phase 3 trial for bladder cancer therapy Apellis...
2023-10-05 07:30:43 ET More on Merck Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck: A Blue-Chip Dividend Stock Worth Buying US government to stop distributing Merck's CO...
2023-09-27 08:59:28 ET Summary Poseida Therapeutics exhibits robust financials with Q2 2023 collaboration revenue surging to $20.01M and a recent $50M Astellas investment extending its cash runway. Despite stock underperformance, Poseida's diversified CAR-T pipeline shows momentum...
2023-09-22 06:49:12 ET More on Merck Seeking Alpha’s Quant Rating on Merck Historical earnings data for Merck Financial information for Merck Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck: A Blue-Chip Dividend St...
2023-09-19 09:29:45 ET More on Astellas, Apellis, etc. Sticking With Apellis: Navigating Syfovre's Safety Measures In A Volatile Market Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade) Wells Fargo ups Apellis to overweight, stock climbs ...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc Company Name:
ALPMF Stock Symbol:
OTCMKTS Market:
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...